Sk Life Science Inc.

Address: 461 From Road Fl 5

Sponsor Overview

assignment

Specializations

Epilepsy and seizure disorders

Sk Life Science Inc. focuses on clinical research in epilepsy, with particular attention to primary generalized tonic-clonic seizures, partial-onset seizures, and partial-onset (focal) seizures.

Primary generalized tonic-clonic seizures
Partial-onset seizures
Partial-onset (focal) seizures

The sponsor’s research activity includes both adult and pediatric populations, reflecting a therapeutic interest in seizure control across a broad age range.

Lennox-Gastaut syndrome

The company also supports studies in Lennox-Gastaut syndrome, a severe developmental and epileptic encephalopathy associated with multiple seizure types, including drop seizures.

Lennox-Gastaut syndrome
Drop seizures
Tonic, atonic, and tonic-clonic seizures

This area highlights interest in difficult-to-control seizure syndromes affecting both pediatric and adult patients.

Cenobamate development in seizure management

Sk Life Science Inc. is actively involved in clinical programs centered on cenobamate for seizure disorders, with research spanning adjunctive therapy and evaluation of treatment effects in generalized and focal epilepsies.

Cenobamate
Adjunctive treatment
Safety and tolerability

Its clinical portfolio includes work in both adult and pediatric epilepsy populations.

Pediatric neurology

A notable part of the sponsor’s research landscape is the study of seizure disorders in children and adolescents, including evaluation of pharmacokinetics and treatment response in younger patients.

Pediatric subjects
Pharmacokinetics
Seizure disorders in children

This emphasis supports therapeutic development for age-specific epilepsy care.

Sponsored Trials

Trial Name	Country	Status
Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Therapy for Lennox-Gastaut Syndrome-Associated Seizures in Pediatric and Adult Patients	Germany Greece Hungary Italy Poland Portugal Spain	Recruiting
Evaluation of Cenobamate as Adjunctive Therapy in Patients Aged 12 and Older with Primary Generalized Tonic-Clonic Seizures: A Randomized, Double-Blind, Placebo-Controlled Study	Germany Hungary Poland Slovakia Spain	Not Recruiting
Evaluation of Safety and Efficacy of Cenobamate in Pediatric Patients with Partial-Onset Seizures: An Open-Label Clinical Trial	Germany Hungary Poland Spain	Not Recruiting
Long-term Safety Evaluation of Cenobamate as Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures: A Multicenter Open-label Extension Study	Germany Hungary Poland Slovakia Spain	Not Recruiting
Pharmacokinetic Dose-Escalation Study of Cenobamate in Pediatric Patients with Partial-Onset Seizures	Hungary Spain	Not Recruiting